Adaptive Biotechnologies Corporation $ADPT Stake Cut by Braidwell LP

Braidwell LP cut its holdings in shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) by 80.9% in the third quarter, HoldingsChannel reports. The fund owned 736,014 shares of the company’s stock after selling 3,127,093 shares during the quarter. Braidwell LP’s holdings in Adaptive Biotechnologies were worth $11,011,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in ADPT. Ameriprise Financial Inc. lifted its position in shares of Adaptive Biotechnologies by 84.3% in the third quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock worth $89,337,000 after purchasing an additional 2,731,648 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its position in Adaptive Biotechnologies by 544.0% during the third quarter. Arrowstreet Capital Limited Partnership now owns 2,441,402 shares of the company’s stock valued at $36,523,000 after purchasing an additional 2,062,282 shares in the last quarter. First Trust Advisors LP grew its position in Adaptive Biotechnologies by 4,802.2% during the second quarter. First Trust Advisors LP now owns 741,306 shares of the company’s stock valued at $8,636,000 after purchasing an additional 726,184 shares in the last quarter. Hillsdale Investment Management Inc. acquired a new position in Adaptive Biotechnologies in the 2nd quarter valued at approximately $6,618,000. Finally, Rhenman & Partners Asset Management AB acquired a new position in Adaptive Biotechnologies in the 3rd quarter valued at approximately $7,405,000. Institutional investors and hedge funds own 99.17% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Wall Street Zen lowered shares of Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th. JPMorgan Chase & Co. upped their price target on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock an “overweight” rating in a research note on Friday, February 6th. TD Cowen reiterated a “buy” rating on shares of Adaptive Biotechnologies in a report on Friday, February 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Wednesday, January 21st. Finally, Piper Sandler set a $21.00 target price on Adaptive Biotechnologies in a research note on Friday, February 6th. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $18.25.

Adaptive Biotechnologies Stock Up 5.8%

ADPT stock opened at $13.17 on Friday. The firm has a 50 day moving average of $16.55 and a two-hundred day moving average of $15.87. Adaptive Biotechnologies Corporation has a 12 month low of $6.68 and a 12 month high of $20.76. The company has a market capitalization of $2.03 billion, a price-to-earnings ratio of -32.92 and a beta of 2.19.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its quarterly earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.10. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 46.68%. The business had revenue of $71.68 million for the quarter, compared to the consensus estimate of $59.38 million. During the same quarter last year, the firm earned ($0.23) EPS. Adaptive Biotechnologies’s revenue for the quarter was up 51.0% on a year-over-year basis. On average, research analysts expect that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current fiscal year.

Key Stories Impacting Adaptive Biotechnologies

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Recent fundamental backdrop: Adaptive’s Feb. 5 quarterly report showed an EPS beat and revenue that was up ~51% year-over-year, supporting investor confidence heading into March. MarketBeat ADPT profile
• Neutral Sentiment: Short-interest print for March shows 0 shares and NaN changes (likely a reporting error). That data point provides no clear bearish signal and may have contributed to lower perceived short pressure. (No reliable short-interest signal.)
• Negative Sentiment: Significant insider selling on Mar. 11–13: combined, company executives and insiders sold roughly 1.25M shares for about $16.6M in proceeds, materially reducing several insiders’ stakes (examples below). This coordinated selling can be perceived negatively by investors as supply into the market or insiders taking liquidity. Filings: CEO Chad M. Robins (470,167 sh, ~$6.19M) Chad Robins Form 4; Harlan S. Robins (470,266 sh, ~$6.19M) Harlan Robins Form 4; COO Julie Rubinstein (160,643 sh across filings) Julie Rubinstein Form 4; CFO Kyle Piskel (18,672 sh) Kyle Piskel Form 4; Sharon Benzeno (63,103 sh) Sharon Benzeno Form 4; Susan Bobulsky (41,338 sh) Susan Bobulsky Form 4; Francis Lo (30,593 sh) Francis Lo Form 4.

Insider Activity

In other Adaptive Biotechnologies news, insider Sharon Benzeno sold 63,103 shares of the firm’s stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $13.17, for a total transaction of $831,066.51. Following the transaction, the insider directly owned 272,751 shares in the company, valued at $3,592,130.67. This trade represents a 18.79% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Francis Lo sold 113,890 shares of the business’s stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $15.57, for a total value of $1,773,267.30. Following the completion of the sale, the insider directly owned 315,978 shares of the company’s stock, valued at $4,919,777.46. This represents a 26.49% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 2,464,588 shares of company stock valued at $36,222,545. Corporate insiders own 6.40% of the company’s stock.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.